In addition to its CNS focus, Jupiter is evaluating opportunities in longevity and metabolic health. Emerging data suggests that JOTROL’s inhibition of NLRP3, when combined with GLP-1 treatments, ...

Jupiter Neurosciences (JUNS) announced a strategic focus on targeting the NLRP3 inflammasome in all upcoming clinical trials. This shift aims ...

With its ability to safely reach therapeutic levels in plasma and cross the blood-brain barrier, JOTROL represents a groundbreaking advance for targeting neuroinflammatory pathways like NLRP3.

With its ability to safely reach therapeutic levels in plasma and cross the blood-brain barrier, JOTROL represents a groundbreaking advance for targeting neuroinflammatory pathways like NLRP3. "By ...

In addition to its CNS focus, Jupiter is evaluating opportunities in longevity and metabolic health. Emerging data suggests that JOTROL’s inhibition of NLRP3, when combined with GLP-1 treatments, ...

Results We observed that MSU and CPP crystals led to a metabolic rewiring toward the aerobic glycolysis pathway explained by an increase in GLUT1 plasma membrane ... and treatment with either ...

A Potential Therapeutic Target for Steroid Resistant Asthma,” published in the December 2024 issue of Allergy and Immunology ...

Objectives The objectives were to identify intracellular pathways induced by CPPD crystals and leading to NLRP3 activation and IL-1β production. Conclusions IL-1β production triggered by m- and t-CPPD ...

Isoliquiritigenin mitigates inflammatory responses by upregulating Sirt-1 activity and modulating the NF-κB and NLRP3 pathways, leading to reduced collagen accumulation in diabetic kidney disease and ...